ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: A report of the ACCF/AHA/ACP task force on clinical competence and training

Gary S. Francis, Barry H. Greenberg, Daphne T. Hsu, Brian E. Jaski, Mariell Jessup, Martin M. Lewinter, Francis D. Pagani, Ileana L. Pia, Marc J. Semigran, Mary Norine Walsh, David H. Wiener, Clyde W. Yancy

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations
Original languageEnglish (US)
Pages (from-to)424-453
Number of pages30
JournalJournal of the American College of Cardiology
Volume56
Issue number5
DOIs
StatePublished - Jul 27 2010

Bibliographical note

Funding Information:
Committee Member Consulting Fees/Honoraria Speaker Ownership/Partnership/Principal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Gary S. Francis (Chair) • ARCA BioPharma, Inc. • Biosite Inc. • Boehringer Ingelheim • Forest • GlaxoSmithKline • Medtronic • Nile • Nitromed • Novartis • Otsuka • Scios, Inc. None None • National Institutes of Health ⁎ None None Barry H. Greenberg • ARCA BioPharma, Inc. • AstraZeneca • CHF Solutions • GlaxoSmithKline ⁎ • Nitromed • Orqis Medical ⁎ • Sanofi-Aventis • AstraZeneca ⁎ • GlaxoSmithKline ⁎ • Medtronic • Merck ⁎ • Nitromed • Novartis • Scios, Inc. None None None None Daphne T. Hsu • Berlin Heart, Inc. • Merck None None None None None Brian E. Jaski • Boston Scientific • CHF Solutions • GlaxoSmithKline None None None None Mariell Jessup • Acorn • CardioMems • GlaxoSmithKline • Medtronic • Scios, Inc. • Ventracor None None • Scios, Inc. None None Martin M. LeWinter • Medtronic • Merck • Novartis • Novartis None • Medtronic ⁎ • Novartis ⁎ None None Francis D. Pagani None None None • Terumo Heart Corporation • Thoratec Corporation None None Ileana L. Piña • Food and Drug Administration, Center for Devices and Radiological Health ⁎ • Sanofi-Aventis • Astellas • AstraZeneca • Novartis None • National Institutes of Health ⁎ None None Marc J. Semigran • GlaxoSmithKline • Medtronic None None None None None Mary Norine Walsh • BioControl • Boston Scientific • Medtronic • St. Jude • UnitedHealthcare • GlaxoSmithKline • Scios, Inc. None None None None David H. Wiener None None None None None None Clyde W. Yancy, Jr. • Arc Discovery • GlaxoSmithKline • Medtronic • NitroMed • Scios, Inc. • GlaxoSmithKline • Novartis None None None None This table represents the relationships of committee members with industry and other entities that were reported orally at the initial writing committee meeting and updated in conjunction with all meetings and conference calls of the writing committee during the document development process. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships noted in this table are modest unless otherwise noted. ⁎ Significant (greater than $10 000) relationship. Appendix 2

Funding Information:
External Reviewer Representation Consultant Speaker Ownership/ Partnership/ Principal Research Salary Institutional, Organizational, or Other Financial Benefit Expert Witness Allen S. Anderson Official Reviewer—ISHTL None None None None None None • Defense, medical malpractice, 2008 • Defense, medical malpractice, 2009 Roberta C. Bogaev Official Reviewer—ISHLT • Boston Scientific • Thoratec • Thoratec None • Thoratec • XDC None None None Alfred A. Bove Official Reviewer—ACCF Board of Trustees None None None None None None None Maria Crespo-Liero Official Reviewer—ISHLT None None None • Astellas Pharma • Novartis • Roche • Wyeth None None None Steven Durning Official Reviewer—ACP None None None None None None None Charin L. Hanlon Official Reviewer—ACP None None None None None None None Paul J. Hauptman Official Reviewer—AHA • Biocontrol Medical ⁎ • GlaxoSmithKline • GlaxoSmithKline None • Amgen • Novacardia/Merck ⁎ • Novartis None None None Paul A. Heidenreich Official Reviewer—AHA None None None None None None None Marvin A. Konstam Official Reviewer—HFSA • AstraZeneca • Biogen • Boehringer-Ingleheim • Merck ⁎ • Novartis • Otsuka ⁎ • Sanofi-Aventis ⁎ None • Orqis Medical ⁎ None • Orqis Medical ⁎ None None Wai Hong W. Tang Official Reviewer—HFSA • Amgen • Boston-Scientific • Medtronic • Merck • Abbott Diagnostics • NxStage None • Abbott Diagnostics None None None Howard H. Weitz Official Reviewer—CCS Task Force Lead Reviewer None None None None None None None Mark J. Zucker Official Reviewer—ACCF Board of Governors • Circulite • Organ Transport Systems None None • Acorn Cardiovascular • Actelion • Biogen • Bioheart • Gilead • Ventracor None None None Charles E. Canter Content Reviewer • Blue Cross Blue Shield • University of Miami • St. Louis Children's Hospital Symposia, 2008 None • NIH 1U01A1077867-01 ⁎ • NIH NL068210 • NIH NL053391-11 • NIH 1-P50HL074732-01 ⁎ None None • Defense, heart failure, 2008 • Defense, heart failure, 2007 • Defense, heart failure, 2007 Jeffrey A. Feinstein Content Reviewer—AC/PC Council None None None None None None None Gerard R. Martin Content Reviewer—AC/PC Council None None None None None None None David Rosenthal Content Reviewer • Berlin Heart None None None None None None Robert N. Vincent Content Reviewer—AC/PC Council None None None None None None None This table represents the relationships of peer reviewers with industry and other entities that were disclosed at the time of peer review. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. ACCF indicates American College of Cardiology Foundation; ACP, American College of Physicians; AC/PC, Adult Congenital and Pediatric Cardiology Council; AHA, American Heart Association; CCS, clinical competence statement; HFSA, Heart Failure Society of America; ISHLT, International Society of Heart and Lung Transplantation. ⁎ Indicates significant relationship.

Keywords

  • ACCF Clinical Competence Statement
  • cardiac transplant
  • competence
  • heart failure

Cite this